Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA4 | P22748 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 2/20 | 0.45 |
| ▸ | MC3R | P41968 | 2/20 | 0.45 |
| ▸ | MC1R | Q01726 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 3/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085039 | 1.00 | GBA1 (0.50) | GBA1CA1CA2CA4CA9 | |
| SCHEMBL2085038 | 1.00 | GBA1 (0.50) | GBA1CA1CA2CA4CA9 | |
| SCHEMBL28045116 | 0.87 | CA1 (0.62) | CA1CA2CA4CA9SLC6A2 | |
| SCHEMBL590923 | 0.87 | CA1 (0.62) | CA1CA2CA4CA9SLC6A2 | |
| SCHEMBL18862950 | 0.84 | HSD11B1 (0.48) | MC4RMC3RMC1RGABRA1GABRG2 | |
| SCHEMBL18862951 | 0.84 | HSD11B1 (0.48) | MC4RMC3RMC1RGABRA1GABRG2 | |
| SCHEMBL873789 | 0.82 | NR1H2 (0.51) | GBA1CA1CA2CA4CA9 | |
| SCHEMBL2083157 | 0.82 | NR1H2 (0.51) | GBA1CA1CA2CA4CA9 | |
| SCHEMBL873617 | 0.82 | NR1H2 (0.51) | GBA1CA1CA2CA4CA9 | |
| SCHEMBL23459127 | 0.81 | SCD5 (0.57) | KMT2AMC4RMC3RMC1RDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989188-B1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2015-07-22 | — | — | EP | disclosed |
| EP-2562168-B1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2014-04-16 | — | — | EP | disclosed |
| US-8501745-B2 | Piperazine PDE4 inhibitors and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-08-06 | — | — | US | disclosed |
| EP-2562168-A1 | Therapeutic piperazines as PDE4 inhibitors | Helicon Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8338405-B2 | Therapeutic piperazines | DART NEUROSCIENCE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110065689-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
| US-20110065688-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE LLC | 2011-03-17 | — | — | US | disclosed |
| US-7829713-B2 | Therapeutic piperazines | HELICON THERAPEUTICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-1989188-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | Helicon Therapeutics, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007100852-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | HELICON THERAPEUTICS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070203124-A1 | Therapeutic Piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203124-A1 | Therapeutic Piperazines | PDE4A, PDE4B, PDE12 | GBA1 849/4885CA1 681/4885CA2 1141/4885 |
| US-20110065688-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE12 | GBA1 849/4885CA1 681/4885CA2 1141/4885 |
| US-20110065689-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE12 | GBA1 849/4885CA1 681/4885CA2 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.